Artículo de revisión

← vista completa

Publicado el 22 de enero de 2016 | http://doi.org/10.5867/medwave.2016.01.6372

Vegetales como nuevas drogas psicoactivas: una revisión narrativa

Vegetables as new psychoactive drugs: a narrative review

Beatriz Rodríguez Salgado, Jorge Gómez-Arnau Ramírez, Daniel Sánchez Mateos, Helen Dolengevich Segal

Abstract

There is growing interest in plants with psychoactive effects among consumers with different levels of experience. This has generated a need for updated knowledge among medical professionals and other health workers. These plants, which may be used in shamanic healing ceremonies or rituals or just for traditional purposes, have emerged in the Western world as new psychoactive drugs; largely thanks to the ease of purchase, sale, cultivation and exchange of information that the Internet offers. This review summarizes the current knowledge about the most important psychoactive plants, either by their mention in Internet forums or harm-reduction portals or by their allusion in scientific texts.

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Beatriz Rodríguez Salgado

Centro de Salud Mental de San Blas, Hospital Ramón y Cajal, Madrid, España

Castillo de Ucles 35, San Blas-Canillejas, Madrid, España

Jorge Gómez-Arnau Ramírez

Hospital Universitario del Henares, Madrid, España

Daniel Sánchez Mateos

Hospital La Fe, Valencia, España

Helen Dolengevich Segal

Hospital Universitario del Henares, Madrid, España

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Rodríguez Salgado B, Gómez-Arnau Ramírez J, Sánchez Mateos D, Dolengevich Segal H. Vegetables as new psychoactive drugs: a narrative review. Medwave 2016;16(01):e6372 doi: 10.5867/medwave.2016.01.6372

Envío 01/11/2015

Aceptación 02/01/2016

Publicación 22/01/2016

Indice

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Keywords

herbal highs, psychoactive drugs, salvia, ayahuasca

Provenance and peer review

con revisión por dos pares revisores externos, a doble ciego

Referencias

  1. Schultes RE, Hofmann A. Plantas de los Dioses. México, Fondo de Cultura Económica, 2000.
  2. Dolengevich-Segal H, Rodríguez Salgado B, Gómez-Arnau Ramírez J, Sánchez-Mateos D. New Psychoactive Drugs. Adicciones. 2015 Sep 15;27(3):231-232. | PubMed
  3. Ujváry I. Psychoactive natural products: overview of recent developments. Ann Ist Super Sanita. 2014; 50(1):12-27. | CrossRef | PubMed
  4. Dolengevich Segal H, Gómez-Arnau Ramírez J, Rodríguez Salgado B, Sánchez-Mateos D (editores). Nuevas Drogas Psicoactivas. España: Entheos; 2015.
  5. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am. 2014 Feb;32(1):1-28. | CrossRef | PubMed
  6. United Nations Office on Drugs and Crime. The Challenge of New Psychoactive Substances. 2013, unodc.org [on line]. | Link
  7. Kikura-Hanajiri R, Uchiyama N, Goda Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg Med (Tokyo). 2011 May; 13(3):109-15. | CrossRef | PubMed
  8. Burns L, Roxburgh A, Matthews A, Bruno R, Lenton S, Van Buskirk J. The rise of new psychoactive substance use in Australia. Drug Test Anal. 2014 Jul-Aug; 6(7-8):846-9. | CrossRef | PubMed
  9. Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003; 306(1):73-83. | PubMed
  10. Ott J. Pharmacotheon. España: Los Libros de la Liebre de Marzo; 2000.
  11. Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol. 2015; 29(3):241-53. | CrossRef | PubMed
  12. Drugs-Forum 2003-2015, drugs-forum.com [on line]. | Link
  13. Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 2015; 89(8):1151-73. | CrossRef | PubMed
  14. Barbanoj MJ, Riba J, Clos S, Giménez S, Grasa E, Romero S. Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl). 2008 Feb;196(2):315-26. | PubMed
  15. Winkelman M. Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Curr Drug Abuse Rev. 2014;7(2):101-16. | PubMed
  16. Schmidt MM, Sharma A, Schifano F, Feinmann C. "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. Forensic Sci Int. 2011 Mar 20; 206(1-3):92-7. | CrossRef | PubMed
  17. Font Quer P. Antófitos, Papaveráceas. En: Plantas Medicinales. El Dioscórides renovado, España: Editorial Península; 2005:242-4.
  18. Mességué M. Amapola. En: Mi herbario de salud. España: Plaza & Janes;1975: 64-6.
  19. Günaydın YK, Dündar ZD, Çekmen B, Akıllı NB, Köylü R, Cander B. Intoxication due to Papaver rhoeas (Corn Poppy): Five Case Reports. Case Rep Med. 2015;2015:321360. | CrossRef | PubMed
  20. El País, 14/06/1995, Martínez A. Un hombre muere tras beber una tisana de amapolas. El País. 14/06/1995; Archivo [on line]. | Link
  21. Gonullu H, Karadas S, Dulger AC, Ebinc S. Hepatotoxicity associated with the ingestion of Papaver Rhoease. J Pak Med Assoc. 2014;64(10):1189-90. | PubMed
  22. Azerty. "Concentrated Decoction: An Experience with Poppies - California (ID 63290)". Erowid.org. Jan 21, 2010. erowid.org [on line]. | Link
  23. TEK. “Guide To Making (a Sort Of) Laudanum, (A step by step pictorial)”. Drugs-forum.org. April 4, 2008 [on line]. | Link
  24. Kalav YN, Sariyar G. Alkaloids from Turkish Papaver rhoeas. Planta Med. 1989;55(5):488. | PubMed
  25. Escohotado A. Sección primera. La Era Pagana. 4. La Ebriedad Sagrada. III. La América Precolombina. 2. La civilización andina. b. Otros estimulantes americanos. En: Historia General de las Drogas. España, Espasa Calpe; 1998.
  26. The Ephedra site. Clinical Toxicology Review, Vol. 18, No. 10 July 1996. EPHEDRA ('MA HUANG') [on line]. | Link
  27. JIFE (Junta Internacional de Fiscalización de Estupefacientes). Decimocuarta edición, enero de 2015. Lista Roja. Lista de precursores y sustancias químicas utilizados frecuentemente en la fabricación ilícita de estupefacientes y sustancias sicotrópicas sometidos a fiscalización internacional. [on line]. | Link
  28. Avois L, Robinson N, Saudan C, Baume N, Mangin P, Saugy M. Central nervous system stimulants and sport practice. Br J Sports Med. 2006;40 Suppl 1:i16-20. | PubMed
  29. Agencia Mundial Antidopaje, 20 de septiembre de 2014. El Código Mundial Antidopaje. La lista de prohibiciones 2015. Estándar internacional [on line]. | Link
  30. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003 Mar 26;289(12):1537-45. | PubMed
  31. Zell-Kanter M, Quigley MA, Leikin JB. Reduction in ephedra poisonings after FDA ban. N Engl J Med. 2015 May 28;372(22):2172-4. | CrossRef | PubMed
  32. Smith MT, Crouch NR, Gericke N, Hirst M. Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. J Ethnopharmacol. 1996;50(3):119-30. | PubMed
  33. Harvey AL, Young LC, Viljoen AM, Gericke NP. Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. J Ethnopharmacol. 2011 Oct 11;137(3):1124-9. | CrossRef | PubMed
  34. Terburg D, Syal S, Rosenberger LA, Heany S, Phillips N, Gericke N, Stein DJ, van Honk J. Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology. 2013;38(13):2708-16. | CrossRef | PubMed
  35. Al-Mugahed L. Khat chewing in Yemen: turning over a new leaf. Bull World Health Organ. 2008;86(10):741-2. | PubMed
  36. Gebissa E. Khat in the Horn of Africa: historical perspectives and current trends. J Ethnopharmacol. 2010 Dec 1;132(3):607-14. | CrossRef | PubMed
  37. Wabe NT. Chemistry, pharmacology, and toxicology of khat (catha edulis forsk): a review. Addict Health. 2011;3(3-4):137-49. | PubMed
  38. Griffiths P, Lopez D, Sedefov R, Gallegos A, Hughes B, Noor A, et al. Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol. 2010 Dec 1;132(3):578-83. | CrossRef | PubMed
  39. Kalix P. Khat: a plant with amphetamine effects. J Subst Abuse Treat. 1988;5(3):163-9. | PubMed
  40. Nencini P, Ahmed AM. Khat consumption: a pharmacological review. Drug Alcohol Depend. 1989 Jan;23(1):19-29. | PubMed
  41. Corkery JM, Schifano F, Oyefeso A, Ghodse AH, Tonia T, Naidoo V, et al. Overview of literature and information on "khat-related" mortality: a call for recognition of the issue and further research. Ann Ist Super Sanita. 2011;47(4):445-64. | CrossRef | PubMed
  42. Odenwald M, Neuner F, Schauer M, Elbert T, Catani C, Lingenfelder B, Hinkel H, Häfner H, Rockstroh B. Khat use as risk factor for psychotic disorders: a cross-sectional and case-control study in Somalia. BMC Med. 2005 Feb 12;3:5. | PubMed
  43. Kassim S, Croucher R, al'Absi M. Khat dependence syndrome: a cross sectional preliminary evaluation amongst UK-resident Yemeni khat chewers. J Ethnopharmacol. 2013 Apr 19;146(3):835-41. | CrossRef | PubMed
  44. Jansen KL, Prast CJ. Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol. 1988;23(1):115-9. | PubMed
  45. Ahmad K, Aziz Z. Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study. J Ethnopharmacol. 2012 May 7;141(1):446-50. | CrossRef | PubMed
  46. The vaults of erowid, 1995 – 2015. [on line]. | Link
  47. Stolt AC, Schröder H, Neurath H, Grecksch G, Höllt V, Meyer MR, et al. Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract. Psychopharmacology (Berl). 2014;231(1):13-25. | CrossRef | PubMed
  48. Boyer EW, Babu KM, Macalino GE. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict. 2007;16(5):352-6. | PubMed
  49. Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila). 2008;46(2):146-52. | CrossRef | PubMed
  50. Dorman C, Wong M, Khan A. Cholestatic hepatitis from prolonged kratom use: a case report. Hepatology. 2015;61(3):1086-7. | CrossRef | PubMed
  51. Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol. 2011;35(4):242-7. | PubMed
  52. Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014 1;139:132-7. | CrossRef | PubMed
  53. Valdés LJ 3rd, Díaz JL, Paul AG. Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol. 1983;7(3):287-312. | PubMed
  54. Hoover V, Marlowe DB, Patapis NS, Festinger DS, Forman RF. Internet access to Salvia divinorum: implications for policy, prevention, and treatment. J Subst Abuse Treat. 2008;35(1):22-7. | PubMed
  55. Nyi PP, Lai EP, Lee DY, Biglete SA, Torrecer GI, Anderson IB. Influence of age on Salvia divinorum use: results of an Internet survey. J Psychoactive Drugs. 2010;42(3):385-92. | PubMed
  56. Currie CL. Epidemiology of adolescent Salvia divinorum use in Canada. Drug Alcohol Depend. 2013 1;128(1-2):166-70. | CrossRef | PubMed
  57. Cunningham CW, Rothman RB, Prisinzano TE. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev. 2011;63(2):316-47. | CrossRef | PubMed
  58. Stiefel KM, Merrifield A, Holcombe AO. The claustrum's proposed role in consciousness is supported by the effect and target localization of Salvia divinorum. Front Integr Neurosci. 2014 Feb 26;8:20. | CrossRef | PubMed
  59. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 2011 1;115(1-2):150-5. | CrossRef | PubMed
  60. Dueweke JR. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: what are the clinical features of Salvia divinorum toxicity? Emerg Med J. 2013;30(4):341-2. | CrossRef | PubMed
  61. Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat. 1994;11(4):379-85. | PubMed
  62. Vastag B. Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'. Science. 2005 Apr 15;308(5720):345-6. | PubMed
  63. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000. | CrossRef | PubMed
  64. Alper K, Bouso JC. Ibogaine: a review. En: Alper KR, Glick SD, Cordell GA (editores). Ibogaine: Proceedings of the First International Conference (Also published as Volume 56 of The Alkaloids Chemistry and Biology). EEUU, San Diego: Academic Press; 2001. | Link
  65. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014 Nov;28(11):993-1000. | CrossRef | PubMed
  66. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008 4;115(1):9-24. | PubMed
  67. Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57(2):398-412. | CrossRef | PubMed
  68. Paling FP, Andrews LM, Valk GD, Blom HJ. Life-threatening complications of ibogaine: three case reports. Neth J Med. 2012;70(9):422-4. | PubMed
  69. Hildyard C, Macklin P, Prendergast B, Bashir Y. A Case of QT Prolongation and Torsades de Pointes Caused by Ibogaine Toxicity. J Emerg Med. 2015 Aug 29. pii:S0736-4679(15)00673-3. | CrossRef | PubMed
  70. Marta CJ, Ryan WC, Kopelowicz A, Koek RJ. Mania following use of ibogaine: A case series. Am J Addict. 2015;24(3):203-5. | CrossRef | PubMed
  71. Orsolini L, Papanti GD, Francesconi G, Schifano F. Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts. Cyberpsychol Behav Soc Netw. 2015;18(5):296-300. | CrossRef | PubMed
  72. Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14(1):15-26. | CrossRef | PubMed
  73. High danger hydrangea? French police hunt gang peddling 'cheaper weed'. The Guardian. 6/02/2014 [on line]. | Link
  74. El peligro de hacerse un porro con hortensias. Faro de Vigo. 8/02/2014 [on line]. | Link
  75. Rempel V, Fuchs A, Hinz S, Karcz T, Lehr M, Koetter U, Müller CE. Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. ACS Med Chem Lett. 2012 Nov 14;4(1):41-5. | CrossRef | PubMed
  76. Boumendjel A, Sotoing Taïwe G, Ngo Bum E, Chabrol T, Beney C, Sinniger V, et al. Occurrence of the synthetic analgesic tramadol in an African medicinal plant. Angew Chem Int Ed Engl. 2013 Nov 4;52(45):11780-4. | CrossRef | PubMed
  77. Kusari S, Tatsimo SJ, Zühlke S, Talontsi FM, Kouam SF, Spiteller M. Tramadol--a true natural product? Angew Chem Int Ed Engl. 2014 Nov 3;53(45):12073-6. | CrossRef | PubMed